Plain-English translation of NCT06131502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing ExAblate MR-guided Focused Ultrasound (a technology that uses sound waves guided by MRI imaging to treat brain areas) for people with severe, treatment-resistant obsessive-compulsive disorder. The procedure targets a small area in the brain called the anterior limb of the internal capsule, which is involved in OCD symptoms. Researchers want to see if this treatment is safe and effective for people whose OCD has not improved with standard medications and therapy.
Many people with OCD do not respond well enough to available treatments like medications and cognitive behavioral therapy, leaving them with severe, disabling symptoms. This trial is testing a new brain procedure that has shown promise in treating other neurological conditions, to see if it can help people with treatment-resistant OCD.
The study has two stages. In Stage 1, participants will receive standard medications and therapy for 6 months, then undergo the focused ultrasound procedure while continuing treatment for another 12 months. In Stage 2, participants will be randomly assigned to either receive the ultrasound procedure or a sham (placebo) procedure along with standard treatment for 12 months; those who receive sham treatment will have the option to receive the real procedure afterward. Throughout the study, participants will have regular visits to assess safety and symptom improvement.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States